Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes.

AIMS: Sequential Anthracycline-Taxane chemotherapy is standard treatment for BC. This study examines the combined impact of low BMI and CYP polymorphisms on treatment response. METHOD: BMI was assessed before chemotherapy, and clinical response was e…

Preview only. Read the full abstract at the source